Source:http://linkedlifedata.com/resource/pubmed/id/16299715
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2005-11-24
|
pubmed:abstractText |
Patients with high viral load (> or =1.0 x 10(5) IU/ml) of hepatitis C virus (HCV) genotype 1b do not achieve high sustained virological response rates to interferon (IFN)/ribavirin combination therapy. Previous studies suggested that pretreatment amino acid (aa) substitution patterns in the HCV core region could affect virological non-response especially in patients who could not achieve HCV-RNA negativity during treatment. The present study evaluated 167 consecutive Japanese adults with high HCV genotype 1b viral load who received combination therapy for > or =24 weeks. A case-control study matched for age, sex, genotype, and viral load was conducted to investigate the predictive factors for virological non-response, especially absolute virological non-response (patients who could not achieve >2 log decline of HCV RNA from baseline during the initial 24 weeks of therapy). Virological non-response was identified in 26.3% of patients, and 45.5% of these were absolute virological non-responders. Multivariate analysis identified ribavirin dose <11.0 mg/kg, moderate-to-severe hepatocyte steatosis, and substitutions of aa 70 and/or 91 in the core region as significant independent factors associated with virological non-response. The majority of absolute virological non-responders had such substitutions in the core region (95.0%), as well as substitution of glutamine at aa 70 and/or methionine at aa 91 (90.0%). In the present work, such substitutions significantly affected the viral kinetics in virological non-responders. The results suggest that viral, host, and treatment-related factors determine the response to IFN/ribavirin combination therapy in patients with high HCV genotype 1b viral load, and that amino acid substitution patterns in the core region is potentially useful pretreatment predictor of virological non-response.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0146-6615
|
pubmed:author |
pubmed-author:AkutaNorioN,
pubmed-author:AraseYasujiY,
pubmed-author:HosakaTetsuyaT,
pubmed-author:IkedaKenjiK,
pubmed-author:KobayashiMarikoM,
pubmed-author:KobayashiMasahiroM,
pubmed-author:KumadaHiromitsuH,
pubmed-author:SaitohSatoshiS,
pubmed-author:SatoJunkoJ,
pubmed-author:SezakiHitomiH,
pubmed-author:SomeyaTakashiT,
pubmed-author:SuzukiFumitakaF,
pubmed-author:SuzukiYoshiyukiY,
pubmed-author:WatahikiSachiyoS
|
pubmed:issnType |
Print
|
pubmed:volume |
78
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
83-90
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16299715-Adult,
pubmed-meshheading:16299715-Aged,
pubmed-meshheading:16299715-Amino Acid Substitution,
pubmed-meshheading:16299715-Antiviral Agents,
pubmed-meshheading:16299715-Case-Control Studies,
pubmed-meshheading:16299715-Drug Therapy, Combination,
pubmed-meshheading:16299715-Fatty Liver,
pubmed-meshheading:16299715-Female,
pubmed-meshheading:16299715-Genotype,
pubmed-meshheading:16299715-Hepacivirus,
pubmed-meshheading:16299715-Hepatitis C,
pubmed-meshheading:16299715-Humans,
pubmed-meshheading:16299715-Interferons,
pubmed-meshheading:16299715-Male,
pubmed-meshheading:16299715-Middle Aged,
pubmed-meshheading:16299715-Mutation, Missense,
pubmed-meshheading:16299715-RNA, Viral,
pubmed-meshheading:16299715-Ribavirin,
pubmed-meshheading:16299715-Risk Factors,
pubmed-meshheading:16299715-Treatment Outcome,
pubmed-meshheading:16299715-Viral Load
|
pubmed:year |
2006
|
pubmed:articleTitle |
Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
|
pubmed:affiliation |
Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan. akuta-gi@umin.ac.jp
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|